(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/245051 A1

(51) International Patent Classification:
C07D 413/14 (2006.01) *A61P 35/00* (2006.01)
C07D 417/14 (2006.01) *A61K 31/381* (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:
PCT/EP2021/064612

(22) International Filing Date:
01 June 2021 (01.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/033,505 02 June 2020 (02.06.2020) US
20212067.1 05 December 2020 (05.12.2020) EP

(71) Applicants: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **VANDERBILT UNIVERSITY** [US/US]; 305 Kirkland Hall, 2201 West End Ave, Nashville, Tennessee 37240 (US).


(72) Inventors: **ABBOTT, Jason**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave, Nashville, Tennessee 37240 (US). **BROEKER, Joachim**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **CUI, Jianwen**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **FESIK, Stephen W.**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **GOLLNER, Andreas**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **HODGES, Tim**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **KAROLYI-OEZGUER, Jale**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **LITTLE, Andrew**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave, Nashville, Tennessee 37240 (US). **MANTOULIDIS, Andreas**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **PHAN, Jason**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **SARKAR, Dhruba**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **SMETHURST, Christian Alan Paul**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **SUN, Qi**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US). **TREU, Matthias**; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **WATERSON, Alex**; VANDERBILT UNIVERSITY, 305 Kirkland Hall, 2201 West End Ave., Nashville, Tennessee 37240 (US).

(74) Agent: **SIMON, ET AL., ELKE Anna Maria** et al.; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER



(I)

(57) Abstract: The present invention encompasses compounds of formula (I), wherein R^{1a}, R^{1b}, R^{2a}, R^{2b}, Z, R^3 to R^5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

WO 2021/245051 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*